Genetic polymorphism and drug interactions: Their importance in the treatment of pain;Polymorphisme génétique et interactions médicamenteuses: Leur importance dans le traitement de la douleur

Canadian Journal of Anesthesia

Volumn 52, Issue 8, 2005, Pages 806-821

  Samer, Caroline Flora ^a   Piguet, Valérie ^a   Dayer, Pierre ^a   Desmeules, Jules A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ALFENTANIL; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CELECOXIB; CITALOPRAM; CLOMIPRAMINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; DIHYDROCODEINE; ESCITALOPRAM; FENTANYL; FLUOXETINE; HYDROCODONE; LORAZEPAM; MEFENAMIC ACID; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXAZEPAM; OXYCODONE; TRAMADOL; UNINDEXED DRUG; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 2D6;

DNA POLYMORPHISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; MEDLINE; PAIN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANIMAL; CLINICAL TRIAL; DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; META ANALYSIS; METABOLISM; PHENOTYPE;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PAIN; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 28444444965     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03021775     Document Type: Review

References (92)

1. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50.
2. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
3. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
4. Shintani M, Ieiri I, Inoue K, et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175-82.
5. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72: 62-75.
6. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13: 473-80.
7. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 alcohol deshydrogenase. Br J Clin Pharmacol 2001; 54: 423-9.
8. Shimamoto J, Ieiri I, Urae A, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56: 65-8.
9. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001, 57: 729-35.
10. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55: 51-61.
11. Brenner SS, Herrlinger C, Dilger K, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42: 283-92.
12. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol 2001, 51: 627-30.
13. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-8.
14. Zanger UM, Raimondo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedeberg's Arch Pharmacol 2004, 369: 23-37.
15. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209.
16. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphism human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-9.
17. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-22.
18. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001; 21: 229-34.
19. Cascorbi I. Pharmacogenetics of cytochrome 2D6: genetic background and clinical implication. Eur J Clin Investig 2003; 33(Suppl 2): 17-22.
20. Yue QY, Hasselstrom J, Svensson JO, Sawe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991; 31: 635-42.
21. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-31.
22. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1988; 152: 411-6.
23. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41: 23-6.
24. Sindrup SH, Arendt-Nielsen L, Brosen K, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992; 42: 587-92.
25. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290: 413-22.
26. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33.
27. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235-9.
28. Desmeules JA. The tramadol option. Eur J Pain 2000; 4(Suppl. A): 15-21.
29. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-44.
30. Desmeules J, Violand C, Piguet V, Kondo M, Dayer P. Role of CYP2D6 in tramadol isomers kinetics and analgesic effects. Clin Pharmacol Ther 2000; 67: 91 (abstract).
31. Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 2003; 135: 9-15.
32. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8.
33. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-93.
34. 1 activity. Clin Pharmacol Ther 1989; 45: 34-40.
35. Desmeules JA, Kondo Oestreicher M, Piguet V, Allaz AF, Dayer P. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J Pharmacol Exp Ther 1999; 288: 607-12.
36. McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004; 98: 1385-400.
37. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375-9.
38. Tyndale RF, Droll KP, Sellers EM. Relevance of deficient CYP2D6 in opiate dependence. Pharmacogenetics 1998; 8: 567-8.
39. Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002; 22: 326-9.
40. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000; 32: 305-16.
41. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004; 24: 621-9.
42. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-95.
43. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-8.
44. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522-34.
45. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92.
46. Desmeules JA, Piguet V, Ehret GB, Dayer P. Pharmacogenetics, pharmacokinetics, and analgesia. In: Mogil JS (Ed.). The Genetics of Pain, Progress in Pain Research and Management. IASP Press; 2004: 211-38.
47. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990; 45: 1-38.
48. Gonzalez FJ, Schmid BJ, Umeno M, et al. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 1988; 7: 79-86.
49. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
50. Niemi M, Backman JT, Fromm ME, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
51. Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22: 211-5.
52. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P450 3A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Dependence 2003, 69: 205-11.
53. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Disp 1998; 26: 257-60.
54. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Disp 1997; 25: 1072-80.
55. Kharasch ED, Russel M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36-50.
56. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991; 41: 573-8.
57. Gascon MP, Dayer P, Waldvogel F. Les interactions médicamenteuses du midazolam. Schweiz Med Wochenschr 1989; 119: 1834-6.
58. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human "MDR1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-8.
59. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33.
60. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
61. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-21.
62. Clement Jerdi M, Desmeules J, Dayer P. La glycoprotéine P: un transporteur de médicaments à ne pas négliger. Med Hyg 2004; 62: 704-9.
63. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584-94.
64. Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002; 96: 913-20.
65. Oude Elferink RP, Zadina J. MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 2001; 22: 2015-20.
66. 2.5] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 1998; 287: 545-52.
67. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 1998; 15: 599-605.
68. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92: 1392-9.
69. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231-7.
70. Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13: 651-60.
71. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74: 543-54.
72. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2003; 57: 600-10.
73. Kharasch ED, Hoffer C, Altuntas TG, Whittington D. Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 2004; 44: 224-33.
74. Drewe J, Ball HA, Beglinger C, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000; 50: 237-46.
75. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lotsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74: 303-11.
76. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40S-8S.
77. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
78. Zhou H, Tong Z, McLeod JF. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 2004; 44: 120-34.
79. Jerdi MC, Daali Y, Oestreicher MK, Cherkaoui S, Dayer P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 2004; 35: 1203-12.
80. Jannetto PJ, Laleli-Sahin F, Wong SH. Pharmacogenomic genotyping methodologies. Clin Chem Lab Med 2004; 42: 1256-64.
81. Collins FS. Microarrays and macroconsequences. Nat Genet 1999; 21(1suppl): 1-51.
82. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
83. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likehood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-58.
84. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
85. Poulsen L, Brose K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects, Eur J Clin Pharmacol 1996; 51: 289-95.
86. Heiskanen T, Olkkola T, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone, Clin Pharmacol Ther 1998; 64: 603-11.
87. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54: 463-72.
88. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-52.
89. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple doing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004; 44: 1132-42.
90. Moghadamnia AA, Rostami-Hodjegan A, Abdul-Manap R, Wright CE, Morice AH, Tucker GT. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br J Clin Pharmacol 2003; 56: 57-67.
91. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003; 55: 649-73.
92. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.